Exenatide and Cardiac Energetics in Type 2 Diabetes

• Research type

  Research Study

• Full title

  Exenatide and Cardiac Energetics in Type 2 Diabetes

• IRAS ID

  16388

• Contact name

  Martin Stevens

• Eudract number

  2009-012794-35

• ISRCTN Number

  N/A

• Research summary

  Exenatide (Byetta TM) will be given in normal therapeutic doses to patients with type two diabetes to determine if it will improve the cardiac energetic status over 26 weeks compared to patients on Insulin Glargine (Lantus TM). A series of non-invasive heart tests will be undertaken before and after exenatide treatment in participants to uncover if exenatide exerts a protective cardiovascular and metabolic effect.

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  09/H1208/34

• Date of REC Opinion

  20 Aug 2009

• REC opinion

  Further Information Favourable Opinion